Page 562 - fbkCardioDiabetes_2017
P. 562

538          Initiation & Intensification of Insulin Therapy in T2DM








                              BIL treatment resulted in significantly lower rates of nocturnal
                             hypoglycemia compared with insulin glargine in T1DM and T2DM


























                         a Data were adjusted for baseline hypoglycemia characteristics;  b Significant difference at endpoint after
                         adjusting for baseline; Note: a hypoglycemic event was defined as a blood glucose level of ≤70 mg/dL
                         (3.9 mmol/L) or, where blood glucose was not determined, as signs or symptoms of hypoglycemia 1

                          1. Rosenstock J et al. Diabetes Care 2013;36:522-8; 2. Bergenstal RM et al. Diabetes Care 2012;35:2140-7


                            BIL was associated with weight loss in

                                        T1DM and T2DM patients


                                                  Weight change from baseline
                                   Mean weightchange in T1DM a             Mean weightchange in T2DM
                              1.0                                    1.0

                              0.5                                    0.5

                                                     Δ 1.9 kg,                               Δ 0.8 kg,
                              0.0                     P<.001         0.0                      P<.001
                              -0.5                                   -0.5


                              -1.0                                   -1.0

                              -1.5                                   -1.5
                                    Insulin glargine                        Insulin glargine
                                    BIL                                     BIL

                           a Crossover design of T1DM study required analysis by least squares means


                           Jacober SJ et al. Diabetes Obes Metab 2014;16:351-6





                                                         GCDC 2017
   557   558   559   560   561   562   563   564   565   566   567